Q-omics provides the consensus-scored MIR6737 profile across patient tissues and cancer cell-line models. MIR6737 expression is associated with patient survival in 10 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, MIR6737 is differentially expressed in 1, with the highest sampling consensus in HNSC. Additionally, MIR6737 RNA expression shows 1,573 significant gene co-expression associations, with the highest sampling consensus in SKCM. Together, these results highlight LIHC, HNSC, and SKCM as cancer lineages where MIR6737 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR6737 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR6737 survival associations across molecular data types. MIR6737 RNA expression shows survival associations in the most cancer types (10). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR6737 RNA expression–survival associations across cancer types. High MIR6737 expression shows unfavorable associations in LIHC, KIRP, LUAD, READ and LGG, but favorable associations in HNSC. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for MIR6737 RNA expression.
This table summarizes MIR6737 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for MIR6737. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR6737 shows higher tumor expression in HNSC. The HNSC box plot shows higher MIR6737 RNA expression in tumor versus normal tissue (log2 FC = +0.079, t-test p = .042).
This table shows molecular features associated with MIR6737 in patient tissues and cancer cell lines. In patient samples, MIR6737 shows the broadest associations at the RNA and protein expression levels, with SKCM recurring as the lineage with the largest associated feature set.
